RKRiya Karan

Riya Karan

*This is an algorithmically generated author record based on publicly available information.

Riya Karan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decoding Ceftazidime-Avibactam Resistance in Newly Identified Klebsiella pneumoniae Carbapenemase (KPC) 107 Variant by Modulating the Active Site Environment

    by Riya Karan, Kunal Dhankhar, Adarsh Singh, Saroj Kumar Panda, Tanmoy Sen, Parth Sarthi Sen Gupta, Saugata Hazra

    Antibiotic resistance is a serious health concern worldwide, predominantly driven by β-lactamase enzymes that can inactivate most prescribed β-lactam drugs. Carbapenemases are specialized β-lactamases that hydrolyze carbapenems, considered last-resort antibiotics. Insertion variants of Klebsiella pneumoniae carbapenemase (KPC) play a major role in this threat, showing alarming resistance to ceftazidime-avibactam (CZA), a key combination therapy to treat this menace. KPC-107 is a variant with an exceptional 28-residue insertion raised by duplication mutation (Ser-Ser-Pro-Arg-Ala-Val-Thr-Glu-Ser-Leu-Gln-Lys-Leu-Thr-Leu-Gly-Ser-Ala-Leu-Ala-Ala-Pro-Gln-Arg-Gln-Gln-Phe-Val) between Ambler positions 180 and 181, conferring resistance to CZA. Our study employs comprehensive biophysical, biochemical, and biological analyses accompanied by molecular docking and MD simulations, reporting that KPC-107 exhibits 10 times enhanced catalytic efficiency and 4-fold increased MIC value for ceftazidime compared to KPC-2, while its activity against other tested β-lactams is diminished. The reduced Ki value (0.23 ± 0.05 μM) of avibactam against KPC-107, in contrast with KPC-2 (Ki = 0.83 ± 0.1 μM), is further explained by carbamylation and decarbamylation rates. Insertion-induced active site modification might lead to a better binding with ceftazidime, which is reduced in the case of avibactam, which could possibly explain the contrasting behavior of KPC-107 against these ligands, as confirmed by fluorescence spectroscopy and isothermal titration calorimetry (ITC). Molecular docking and MD simulations, including free energy landscape (FEL), principal component analysis (PCA), and radial distribution function (RDF), may further support the binding affinity and the mechanisms underlying ceftazidime resistance. Our findings suggest that KPC-107 adapts distinct mechanistic strategies to evade CZA armor by enhanced ceftazidime hydrolysis while compromising increased inhibition by avibactam, strengthening its role in antibiotic resistance evolution.


  • Mechanistic insights into ESBL activity of subclass A2 in Class A beta-lactamase revealing a distinct strategy towards conferring drug resistance

    by Riya Karan, Anish Pyne, Saroj K. Panda, Parth S. Sen Gupta, Saugata Hazra

    The twenty first century has witnessed challenges with antimicrobial resistance (AMR) emerging as a critical global threat. Among its most concerning is antibiotic resistance (ABR), highly linked to beta-lactamases. Among others, Class A beta-lactamases, present significantly with functional diversity, although ESBLs are one of the major concerns. A key defence mechanism in Gram-negative bacteria is the overexpression of ESBLs (Extended spectrum beta-lactamases) which spread across the bacterial population through horizontal gene transfer causes serious nosocomial infections. Since ESBLs have developed to increase their substrate specificity and hydrolyse most cephalosporins, penicillins, and monobactams, research into them is urgently needed.However, despite attempts functional classification, based on sequence identity, fold similarity, the presence or absence of insertions, particularly in loop regions and mode of action, a universally accepted framework remains elusive. Previous studies have broadly categorized Class A beta-lactamases into subclasses A1 and A2, yet the mechanistic intricacies of subclass A2 only as ESBL demand a more nuanced, multilevel analysis, underlying their role in antibiotic resistance. To bridge this knowledge gap, we employed on a comprehensive investigation encompassing sequence, structure, molecular docking, and dynamic analyses to elucidate the mechanistic approach of antibiotic resistance profiles for these two subclasses. Our sequence and structural studies revealed differences, particularly in insertions, structural alignments, and loop regions, including the omega loop and loops near the active site. Molecular docking study demonstrated better binding of the bigger substrate in the active site cavity of A2 subclass representatives. Dynamic analyses further confirmed our findings, employing root mean square deviation (RMSD), root mean square fluctuation (RMSF), flexibility of the extended and omega loops, radius of gyration (Rg), solvent-accessible surface area (SASA), clustering, hydrogen bonding patterns, principal component analysis (PCA), and free energy landscape (FEL). This study provides insights into the molecular distinctions and resistance mechanisms of these subclasses, paving the way for advanced research in antibiotic resistance and strengthening novel therapeutic strategies.